ID: ALA5081807

Max Phase: Preclinical

Molecular Formula: C22H22N4O8P2S

Molecular Weight: 564.45

Molecule Type: Unknown

Representations

Canonical SMILES:  CO[C@@H](C(=O)Nc1cccc(-c2nc(NC(P(=O)(O)O)P(=O)(O)O)c3ccsc3n2)c1)c1ccccc1

Standard InChI:  InChI=1S/C22H22N4O8P2S/c1-34-17(13-6-3-2-4-7-13)20(27)23-15-9-5-8-14(12-15)18-24-19(16-10-11-37-21(16)25-18)26-22(35(28,29)30)36(31,32)33/h2-12,17,22H,1H3,(H,23,27)(H,24,25,26)(H2,28,29,30)(H2,31,32,33)/t17-/m1/s1

Standard InChI Key:  LTUUDHLALQIKIJ-QGZVFWFLSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 564.45

Molecular Weight (Monoisotopic): 564.0634

AlogP: 3.74

#Rotatable Bonds: 9

Polar Surface Area: 191.20

Molecular Species: ACID

HBA: 8

HBD: 6

#RO5 Violations: 2

HBA (Lipinski): 12

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 0.88

CX Basic pKa: 4.11

CX LogP: 1.68

CX LogD: -1.49

Aromatic Rings: 4

Heavy Atoms: 37

QED Weighted: 0.16

Np Likeness Score: -1.43

References

1. Lee HF, Lacbay CM, Boutin R, Matralis AN, Park J, Waller DD, Guan TL, Sebag M, Tsantrizos YS..  (2022)  Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase.,  65  (3.0): [PMID:35077178] [10.1021/acs.jmedchem.1c01913]

Source

Source(1):

• Scientific Literature